Development of anti-influenza drugs: II. Improvement of oral and intranasal absorption and the anti-influenza activity of stachyflin derivatives.
The in-vivo anti-influenza-virus activity of Stachyflin derivatives (III and its phosphate ester, III-Phos), a new class of haemagglutinin fusion inhibitor, and the improvement of their absorption after oral or intranasal administration were studied in mice, rats, and ferrets. The absorption of III in PEG 4000 and III-Phos aqueous solution increased about three and four fold in AUC after oral administration to uninfected mice compared with that of 0.5% HPMC (hydroxypropyl-methylcellulose) suspension. Using a mouse influenza virus infection model, significant anti-influenza-virus activity was observed in infected mice treated orally with these compounds dissolved in PEG 4000 or distilled water, respectively, but not in mice treated with 0.5% HPMC. The in-vivo anti-influenza-virus activity in ferrets, a good model for influenza virus infection in man, was also studied. Although the concentration of III in plasma was above the IC50 against the influenza virus strain used for 6h after the oral administration of III in PEG 400 to uninfected ferrets, no in-vivo anti-influenza-virus activity was observed at the same dosage given 4 times daily for 3 days. The intranasal administration of III-Phos, which was expected to have a more notable in-vivo anti-influenza-virus activity, was examined. III-Phos, whose intranasal absorption had been improved by the modification of III with phosphate ester in rats, inhibited viral replication in the nasal cavity and suppressed influenza-virus-induced fever when administered intranasally to infected ferrets. This study demonstrates that intranasally administered compounds with anti-influenza-virus activity must permeate the nasal membranes to produce their anti-influenza-virus effect.
Yoshimoto
J
J
Shionogi Research Laboratories, Shionogi & Co. Ltd, Osaka, Japan.
Yagi
S
S
Ono
J
J
Sugita
K
K
Hattori
N
N
Fujioka
T
T
Fujiwara
T
T
Sugimoto
H
H
Hashimoto
N
N
D000042:Absorption; D000818:Animals; D000998:Antiviral Agents / Q000097:blood / Q000737:chemistry / Q000493:pharmacokinetics*; D004353:Drug Evaluation, Preclinical; D005289:Ferrets; D006801:Humans; D009980:Influenza A virus / Q000187:drug effects* / Q000378:metabolism; D007251:Influenza, Human / Q000188:drug therapy* / Q000378:metabolism; D007421:Intestine, Small / Q000378:metabolism*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009296:Nasal Cavity / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012717:Sesquiterpenes / Q000097:blood / Q000737:chemistry / Q000493:pharmacokinetics*
D000998:Antiviral Agents; D012717:Sesquiterpenes; C120519:stachyflin; C421362:stachyflin III; C421364:stachyflin III, phosphate ester